| 30.98 -0.01 (-0.03%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
PetIQ, Inc. operates as a prominent enterprise in the pet health and wellness sector, with a market presence across the United States and internationally. Its operations are strategically divided into two primary segments: Products and Services. Within its Products division, the company provides a comprehensive range of veterinary prescription medications. This includes crucial treatments for issues like flea and tick control, heartworm prevention, arthritis, thyroid disorders, diabetes management, pain relief, various antibiotics, and other specialized pharmaceuticals. PetIQ is unique in that it both develops and manufactures its own line of exclusive, value-branded products, while also serving as a distributor for numerous established third-party branded medications. Furthermore, it supplies over-the-counter (OTC) medications and related supplies, with a strong emphasis on flea and tick control and behavior management solutions. These OTC offerings are available in diverse formats, such as topical spot-on applications, chewable and oral tablets, and collars. Beyond medications, the company also features health and wellness products, including specialized dental treats and a variety of nutritional supplements for concerns like hip and joint health, general vitamins, and improvements to skin and coat. This extensive product portfolio is marketed under a wide array of brand names, including PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles. The Services segment delivers an extensive suite of veterinary care options. PetIQ manages approximately 2,900 community clinics and wellness centers, frequently hosted within pet retail locations across 42 states. These centers provide essential services such as diagnostic testing, comprehensive vaccination programs, dispensing of prescription medications, microchipping, and routine wellness examinations. With an impressive reach, PetIQ leverages approximately 60,000 distribution points, ensuring its products and services are readily available through diverse channels, including veterinary practices, traditional retail stores, and online e-commerce platforms. Established in 2010, PetIQ, Inc. is headquartered in Eagle, Idaho.
Thu, 24 Apr 2025
PETQ Stock Price, News & Analysis | Petiq - Stock Titan
Tue, 11 Feb 2025
PETQ Leadership Coup: Coty's Former CEO Takes Helm at PetIQ - Strategic Growth Move Signals Major Transformation - Stock Titan
Fri, 25 Oct 2024
PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group - Yahoo Finance
Fri, 09 Aug 2024
petq-20240630 - SEC.gov
Wed, 28 Feb 2024
PetIQ Inc (PETQ) Reports Strong Growth in 2023 with Record Net Sales and Cash Flow - Yahoo Finance
Tue, 07 Nov 2023
PetIQ Inc (PETQ) Reports Record Third Quarter 2023 Results with Net Sales Surging 32% - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|